Upgrade to SI Premium - Free Trial

BMO Capital: 'Eli Lilly (LLY) to Acquire Precision I&I Biotech Merida Bio'

September 1, 2026 9:14 AM
BMO Capital analyst Evan Seigerman reiterated an Outperform rating and $1,400.00 price target on Eli Lilly (NYSE: LLY).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments